BRAIN Biotech AG (BNN) — Cash Flow-to-Debt Ratio
BRAIN Biotech AG (BNN) has a Cash Flow-to-Debt Ratio of -0.07x as of September 2025, meaning its operating cash flow of €-4.28 Million could theoretically repay 0% of its total liabilities (€64.50 Million) in one year. See BNN free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BRAIN Biotech AG Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BRAIN Biotech AG across 14 annual periods. Also explore BRAIN Biotech AG annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BRAIN Biotech AG (2012–2025)
Year-by-year debt coverage analysis for BRAIN Biotech AG. For market capitalisation and broader financial context, see BRAIN Biotech AG market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.14x | €-9.23 Million | €64.50 Million | ▼ -199.1% |
| 2024 | -0.05x | €-3.58 Million | €74.85 Million | ▲ +45.6% |
| 2023 | -0.09x | €-4.22 Million | €47.92 Million | ▼ -159.3% |
| 2022 | -0.03x | €-1.49 Million | €43.74 Million | ▲ +68.8% |
| 2021 | -0.11x | €-3.91 Million | €35.91 Million | ▼ -5.0% |
| 2020 | -0.10x | €-4.77 Million | €46.01 Million | ▼ -50.3% |
| 2019 | -0.07x | €-3.38 Million | €49.03 Million | ▲ +44.2% |
| 2018 | -0.12x | €-5.42 Million | €43.83 Million | ▲ +54.6% |
| 2017 | -0.27x | €-5.76 Million | €21.14 Million | ▲ +35.4% |
| 2016 | -0.42x | €-8.68 Million | €20.59 Million | ▼ -152.8% |
| 2015 | -0.17x | €-4.11 Million | €24.65 Million | ▲ +52.0% |
| 2014 | -0.35x | €-3.90 Million | €11.22 Million | ▲ +46.2% |
| 2013 | -0.65x | €-4.85 Million | €7.51 Million | ▲ +16.7% |
| 2012 | -0.78x | €-5.89 Million | €7.59 Million | — |